Safety and efficacy of Edaravone[Nichiiko] in patients with acute noncardiogenic brain embolism
- Conditions
- acute noncardiogenic brain embolism
- Registration Number
- JPRN-UMIN000004597
- Lead Sponsor
- Takeshi Yamada
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
the investigators must ensure that all subjects being considered to meet the following exclusion criteria or conditions: 1)difficult lifesaving in a coma 2)serum creatinine >= 1.5 mg/dL 3)history of allergy to Edaravone 4)cardiogenic brain embolism 5)hemorrhagic infarction, epidural hemorrhage, intracerebral hemorrhage, intraventricular hemorrhage 6)transient ischemic attack 7)patients are less than 3 months from the last onset in case of reappearance 8)mRS before the onset >= grade 2 9)patients who are administrated the excluded drugs between onset and investigational drug administration 10)patients who are recieved the excluded therapies between onset and investigational drug administration 11)A serious heart disease(e.g heart failure) or hepatic disease(e.g cirrhosis hepatis) to need hospitalization treatment 12)Patients have cancer 13)Patients who are or may be pregnant, who are lactating 14)recent (past 3 months) participation in other clinical trial for investigational agent,the investigator determines this trial participation inadequate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety The investigators examined adverse event, unusual change in laboratory values and vital sign
- Secondary Outcome Measures
Name Time Method Efficacy 1)mRS:at 4 weeks, 3 months after administration 2)NIHSS:at the end of administration, and at 4 weeks, 3 months after administration 3)JCS:at the end of administration